关注
Asger Bach Lund
Asger Bach Lund
Associate Professor, MD, PhD
在 regionh.dk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Glucagon-like peptide 1 in health and disease
A Andersen, A Lund, FK Knop, T Vilsbøll
Nature Reviews Endocrinology 14 (7), 390-403, 2018
4292018
Impaired regulation of the incretin effect in patients with type 2 diabetes
JI Bagger, FK Knop, A Lund, H Vestergaard, JJ Holst, T Vilsbøll
The Journal of Clinical Endocrinology & Metabolism 96 (3), 737-745, 2011
2902011
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
A Lund, T Vilsbøll, JI Bagger, JJ Holst, FK Knop
American Journal of Physiology-Endocrinology and Metabolism 300 (6), E1038-E1046, 2011
1972011
Regulation of glucagon secretion by incretins
JJ Holst, M Christensen, A Lund, J De Heer, B Svendsen, U Kielgast, ...
Diabetes, Obesity and Metabolism 13, 89-94, 2011
1962011
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities
A Lund, FK Knop, T Vilsbøll
European journal of internal medicine 25 (5), 407-414, 2014
1852014
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals
MP Suppli, KTG Rigbolt, SS Veidal, S Heebøll, PL Eriksen, M Demant, ...
American Journal of Physiology-Gastrointestinal and Liver Physiology 316 (4 …, 2019
1822019
Evidence of extrapancreatic glucagon secretion in man
A Lund, JI Bagger, NJ Wewer Albrechtsen, M Christensen, M Grøndahl, ...
Diabetes 65 (3), 585-597, 2016
1742016
The role of glucagon in the pathophysiology and treatment of type 2 diabetes
S Hædersdal, A Lund, FK Knop, T Vilsbøll
Mayo Clinic Proceedings 93 (2), 217-239, 2018
1532018
Glucagon and type 2 diabetes: the return of the alpha cell
A Lund, JI Bagger, M Christensen, FK Knop, T Vilsbøll
Current diabetes reports 14, 1-7, 2014
1502014
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
NC Bergmann, A Lund, LS Gasbjerg, ECE Meessen, MM Andersen, ...
Diabetologia 62, 665-675, 2019
1022019
Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals
JI Bagger, FK Knop, A Lund, JJ Holst, T Vilsbøll
Diabetologia 57, 1720-1725, 2014
842014
Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia
MB Christensen, A Lund, S Calanna, NR Jørgensen, JJ Holst, T Vilsbøll, ...
The Journal of Clinical Endocrinology & Metabolism 103 (1), 288-294, 2018
782018
Glucagon physiology
I Rix, C Nexøe-Larsen, NC Bergmann, A Lund, FK Knop
692015
Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis
MP Suppli, JI Bagger, A Lund, M Demant, G van Hall, C Strandberg, ...
Diabetes 69 (6), 1090-1099, 2020
662020
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion—a review
DS Mathiesen, JI Bagger, NC Bergmann, A Lund, MB Christensen, ...
International journal of molecular sciences 20 (17), 4092, 2019
642019
Oxyntomodulin identified as a marker of type 2 diabetes and gastric bypass surgery by mass-spectrometry based profiling of human plasma
NJW Albrechtsen, D Hornburg, R Albrechtsen, B Svendsen, S Toräng, ...
EBioMedicine 7, 112-120, 2016
592016
No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon …
NC Bergmann, LS Gasbjerg, SM Heimbürger, LSL Krogh, F Dela, ...
Diabetes Care 43 (3), 588-596, 2020
502020
Separate and combined effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes
NC Bergmann, A Lund, LS Gasbjerg, NR Jørgensen, L Jessen, ...
The Journal of Clinical Endocrinology & Metabolism 104 (7), 2953-2960, 2019
482019
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
NJ Johansen, TF Dejgaard, A Lund, C Schlüntz, CS Frandsen, JL Forman, ...
The Lancet Diabetes & Endocrinology 8 (4), 313-324, 2020
472020
Emerging GLP-1 receptor agonists
A Lund, FK Knop, T Vilsbøll
Expert opinion on emerging drugs 16 (4), 607-618, 2011
382011
系统目前无法执行此操作,请稍后再试。
文章 1–20